World Health Organisation (WHO) endorsed the world's first Malaria Vaccine in the hope that it will spur stalled efforts to curb the spread of the parasitic disease.
It is an injectable vaccine targeting P. falciparum, the most prevalent malaria strain in Africa. It is the first and only vaccine to show partial protection in young children. The vaccine's effectiveness at preventing severe cases of malaria in children is only around 30%, but it is the only approved vaccine.
It was developed by British drugmaker GlaxoSmithKline in 1987.
The active substance in Mosquirix is made up of proteins found on the surface of the Plasmodium falciparum parasites (PFP).
It also helps protect against infection of the liver with the Hepatitis B virus.
